引言：骨转移是导致晚期乳腺癌患者生存率下降的主要原因之一。因此，在疾病早期阶段寻找发生这种转移的预后标志物至关重要。目前，癌相关成纤维细胞在肿瘤微环境中占80%成纤维细胞的比例，是研究新生物标志物和开发替代疗法的一个有趣的靶点。本研究评估了早期乳腺癌患者中癌相关成纤维细胞中CD105表达的预后意义。方法：使用免疫组化技术评估浸润性导管癌（n = 342）中CD105表达，并分析其与临床和病理特征的关系。结果：癌相关成纤维细胞中CD105的高表达与转移发生的风险增加相关（p = 0.0003），尤其是骨转移（p = 0.0005）。此外，高CD105表达与转移无病生存期、骨转移无病生存期和总生存期较短相关（p = 0.0002、0.0006和0.0002，分别）。CD105表达也是转移无病生存期、骨转移无病生存期和总生存期的独立预后因子（p = 0.0003、0.0006和0.0001，分别）。讨论：癌相关成纤维细胞中CD105的高表达是早期乳腺癌患者骨转移的独立预后标志物。因此，评估CD105(+)癌相关成纤维细胞对基于个体风险偏好分层的乳腺癌患者的骨转移发展至关重要，从而提高治疗策略和结果。版权所有© 2023年 Giorello、Martinez、Borzone、Padin、Mora、Sevic、Alaniz、Calcagno、García-Rivello、Wernicke、Labovsky和Chasseing。

Introduction: Bone metastasis is one of the causes that mainly decrease survival in patients with advanced breast cancer. Therefore, it is essential to find prognostic markers for the occurrence of this type of metastasis during the early stage of the disease. Currently, cancer-associated fibroblasts, which represent 80% of the fibroblasts present in the tumor microenvironment, are an interesting target for studying new biomarkers and developing alternative therapies. This study evaluated the prognostic significance of the CD105 expression in cancer-associated fibroblasts in early breast cancer patients. Methods: Immunohistochemistry was used to assess CD105 expression in invasive ductal breast carcinomas (n = 342), analyzing its association with clinical and pathological characteristics. Results: High CD105 expression in cancer-associated fibroblasts was associated with an increased risk of metastatic occurrence (p = 0.0003), particularly bone metastasis (p = 0.0005). Furthermore, high CD105 expression was associated with shorter metastasis-free survival, bone metastasis-free survival, and overall survival (p = 0.0002, 0.0006, and 0.0002, respectively). CD105 expression also constituted an independent prognostic factor for metastasis-free survival, bone metastasis-free survival, and overall survival (p = 0.0003, 0.0006, and 0.0001, respectively). Discussion: The high CD105 expression in cancer-associated fibroblasts is an independent prognostic marker for bone metastasis in early breast cancer patients. Therefore, the evaluation of CD105(+) CAFs could be crucial to stratify BCPs based on their individual risk profile for the development of BM, enhancing treatment strategies and outcomes.Copyright © 2023 Giorello, Martinez, Borzone, Padin, Mora, Sevic, Alaniz, Calcagno, García-Rivello, Wernicke, Labovsky and Chasseing.